Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by kuatoliveson Sep 10, 2016 9:29am
161 Views
Post# 25224851

RE:RE:RE:RE:3 more trading days...

RE:RE:RE:RE:3 more trading days...Dunno, but with the (hopeful) approval and the current bond market tantrum, the next 2 weeks will probably be volitile as all hell.  If/when Yosprala gets approved, it will at least provide a bit of a backstop for whatever happens in the next quarter, at least until, like stated, we get to 2017 with a quarter of earnings behind us.

Upon approval, I could see the market trading the stock up only to fork back the gains in the coming weeks, and the temptation there is to sell and re-enter once the dust settles, but it would have to be a helluva run for me to consider doing that as you don't want to be on the sidelines the one day a major deal is announced. Such would be my luck, so when in doubt, stick with buy and hold and ride out the market games. Also, approval of Yosprala immediately makes the company a takeout target, so you never know when an offer would come in. Staying long probably for another year ....



<< Previous
Bullboard Posts
Next >>